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INTRODUCTION 
Human chorionic gonadotropin (HCG) and luteinizing hormone (LH) are glycoprotein 
hormones which, under physiologic condit ions, have clearly dif ferent functions. HCG is 
produced by the trophoblast and is supposed to maintain the funct ion of the corpus 
luteum during the early stages of pregnancy, thus providing the steroids (estrogens and 
progesterone) necessary to promote growth of the uterus and to support the endome-
t r ium. During the second and th i rd trimesters of pregnancy, when the placenta itself 
has taken over the product ion of these steroids, HCG product ion persists, its role during 
this stage of gestation being not well understood yet. 
LH is produced by the anterior pi tui tary gland and plays an important part in the 
regulation of the menstrual cycle. While fol l ic le stimulating hormone (FSH) is respon-
sible for the growth of the fol l ic le, which produces estrogen and stimulates endometrial 
growth, L H , m combinat ion w i th FSH, induces the f inal stages of fol l icular ripening, 
release of the ovum and transformation of the fol l icular remnant to a funct ional corpus 
luteum. 
Under pharmacological condit ions however HCG and LH show striking biological and 
immunological similarities, suggesting that the two hormones might have similar struc-
tures. 
For a better understanding of the studies described m this thesis a short review of some 
chemical, biological, immunological and metabolic properties of these two hormones 
wi l l be given m this in t roduct ion. 
I. Chemical properties: 
Analyt ical studies on the primary structure of HCG and LH have shown similarities 
m their respective amino acid composit ion. The carbohydrate composit ion however 
shows significant differences between the two hormones, the sialic acid (N-acetyl 
neuraminic acid, N A N A ) content of human LH and even more of ovine LH being 
substantially lower than that of HCG (Table I) . 
Recent studies (Papkow et al., 1967; Canfield et al., 1971) have shown the HCG and 
L H molecules to consist of two polypeptide chains (subumts) w i th dif ferent ammoacid 
and carbohydrate composi t ion, but again there appears to be a strong similari ty between 
the corresponding subumts of HCG and L H . 
Bahl (1969) has investigated in more detail the nature of the carbohydrate moiety of 
HCG. Using specific glycosidases he was able to determine the sequence of monosacchari-
des in the carbohydrate chains and has proposed a tentative structure of the carbohydrate 
units (Fig. 1). It is noteworthy that the sialic acid residue is always found m a terminal 
posit ion making it readily accessible to enzymatic removal. 
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T A B L E I. Am ino acid1 and carbohydrate2 composit ion of HCG and LH 
Lysine 
Histidine 
Arginine 
Asparagine 
Threonine 
Serine 
Glutamic acid 
Proline 
Glycine 
Alanine 
'/2 Cystine 
Valine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Total hexose 
Total hexosamine 
Sialic acid 
HCG3 
4.4 
1.8 
6.6 
7.4 
7.3 
9.5 
7.9 
12.2 
5.3 
5.4 
8.6 
7.9 
1.7 
2.4 
6.4 
2.6 
2.4 
11.2 
11.0 
9.0 
HCG4 
4.3 
1.8 
6.5 
8.4 
7.5 
8.4 
8.6 
12.6 
6.0 
5.8 
7.6 
7.3 
0.7 
2.6 
6.7 
2.7 
2.6 
— 
— 
— 
Human LH S 
5.1 
2.7 
5.4 
7.3 
8.4 
8.5 
9.2 
11.3 
6.4 
6.1 
3.4 
8.3 
1.8 
3.3 
5.8 
2.4 
3.4 
11.2 
3.5 
1.7 
Ovine LH S 
6.5 
3.0 
5.6 
5.6 
7.5 
9.2 
9.0 
13.2 
6.3 
8.3 
1.6 
6.6 
1.8 
2.9 
6.9 
2.5 
3.6 
11.8 
6.0 
0.3 
Ovine L H 6 
6.4 
2.7 
4.9 
5.8 
7.6 
6.6 
7.1 
12.2 
6.1 
7.8 
8.8 
6.3 
2.4 
3.3 
5.8 
2.9 
3.2 
7.9. 
7.8 
0.3 
1) recalculated in residues per 100 amino acids 
2) g per 100 g protein 
3) f rom Bahl (1969) 
4) f rom B e l l e t a l (1969) 
5) f rom Kathanet al (1967) 
6) f rom Papkow et al (1965) 
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Fig 1 Tentative structure of the carbohydrate 
chains of HCG (after Bahl, 1969) 
M M M M M GINA - P R O T E I N GINA M M M M M 
GINA GINA GINA GINA GINA GNA GNA GNA GINA GINA GINA GINA 
NA NA NA FU NA NA NA NA NA 
M = mannose 
G = galactose 
FU = fucose 
GINA= N-acetylglucosamme 
GNA = N-acetylgalactosamme 
NA = N-acetyl neuraminic acid 
I I . Biological properties: 
The hormonal actions of HCG and LH in animal experiments are undistmguishable 
f rom each other. Injection of either HCG or LH into sexually immature rodents produces 
dose related changes m mass, gross and microscopic appearance and biochemical compo-
sition of the gonads. In addit ion, both hormones stimulate interstit ial cell secretion of 
estrogens by ovaries and androgens by testes, to produce growth of the accessory organs 
such as the uterus m females and the ventral prostate in males. By an as yet unknown 
mechanism HCG and LH cause a dose related depletion of the ascorbic acid content of 
ovaries of pseudopregnant immature rats. 
These findings have led to the development of various biological assays of wich those most 
current ly used for HCG and LH are the ventral prostate weight (VPW) assay of Greep 
(1938) and the ovarian ascorbic acid depletion (OAAD) assay of Parlow (1961). The 
methods of these assays are described m detail m the first paper of this thesis. Qualitat ively 
these assays cannot always discriminate between HCG and L H . There are however 
discrepancies in the potency estimation of HCG and LH by the O A A D and VPW assays. 
While HCG shows equal biologic act ivi ty when measured m both assays, LH f rom some 
animal species shows considerably higher biologic act ivi ty as measured by O A A D than 
by VPW, when an HCG preparation is used as a standard. Moreover these differences 
m relative potencies seem to be correlated w i th the plasma half life of the dif ferent LH 
preparations (Parlow, 1968). In general, preparations w i th shorter half lives higher relative 
potencies in the O A A D than in the VPW assay. This discrepancy m biological activi ty 
between the two assays is expressed m a so called index of discrimination (OAAD/VPW 
or VPW/OAAD) . A n explanation for this phenomenon could be found in the fact that 
the O A A D assay is a short assay measuring an acute biochemical response 4 hours 
after intravenous injection while the VPW assay is a long assay measuring a chronic 
growth response after 4 days during which the testmaterials are injected subcutaneously. 
It is conceivable that the biologic act ivi ty of LH-preparations w i th a short half-l ife wi l l 
be more "a f fec ted" in a long bio-assay. 
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I I I . Immunologic properties: 
Being protein hormones, HCG and LH have antigenic properties, which means that they 
are able to induce the format ion of antibodies when injected into another species. The 
antigenicity of protein hormones in general has led to the development of radioimmuno-
logical assay methods (Yalow and Berson, 1959, Berson et al., 1964). These assays are 
based upon the quantitat ive inhib i t ion of the reaction between radioactive labelled hor-
mone and its specific ant ibody by unlabelled hormone. As is the case for the biological 
assay methods, radioimmunoassays for HCG and L H are generally not able to discrimi-
nate between these two hormones because of the immunological cross-reactivity between 
human LH and HCG-antibodies (Wide et a l . ,1961,Taymor et al.,1965). A n advantage of 
this cross-reactivity has been that an HCG-anti HCG system can be used for the measure-
ment of LH and vice versa. (Midgley, 1966). 
It is however important to realize that the immunological and biological activities of a 
hormone preparation are not necessarily identical and that these activities are probably 
situated in dif ferent parts of the molecule. In v i t ro mactivation of the biological activi ty 
of HCG by heating does not reduce the immunological activi ty (Wide, 1962). Radiation 
mactivation of HCG has been shown to be greater when assayed biologically than 
immunological ly, suggesting that the structural unit required for immunological activity 
is considerably smaller than that required for biological activi ty (Paul and Odel l , 1964). 
Wide and Hobson (1967) observed changes in the bio- and immuno-potency ratios as 
pregnancy progresses, and concluded that the biological and immunological methods 
used for the assay of HCG do not completely measure the same activi ty. Another 
example of discrepancies between biologic and immunologic activi ty has been reported 
by van Hell et al. and Schuurs et al. (1968) and Wilde (1969). These investigators 
attained high biological activities of around 19,000 lU /mg during pur i f icat ion of HCG, 
while immunological potency did not rise above 5250 lU /mg. It seems obvious that 
immunological methods measure different activities than do biological assays and that 
they provide dif ferent but complementary informat ion (Bagshawe et al., 1966). 
IV . Metabolic properties: 
Besides the differences m sialic acid content the most outstanding biologic difference 
between HCG and L H lies in their metabolic behaviour. Various authors have investigated 
the rate of disappearance of HCG f rom plasma, either fo l lowing delivery of the placenta 
or after injection of HCG into human subjects. Their results show quite consistently that 
the plasma half-life ( T ' / Î ) of HCG in humans varies between 3-11 hours. Parlow and 
Ward (1961) found at T ' / i of 4.9 hours after intravenous injection of a single dose of 
HCG m mature female rats. Table II summarizes the results of the various investigations. 
On the other hand studies on the plasma disappearance rate of LH either fo l lowing 
surgical hypophysectomy or after intravenous injection of L H have shown a considerably 
shorter Т ' / г · In humans the plasma disappearance rate of L H varies between 20-60 
minutes. The Т ' / г of ovine L H is even shorter (Table I I I ) . 
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TABLE II. Plasma disappearance rate of HCG 
Author Experimental design Assay method T1/, (hours) 
Johnson et al. (1950) 
Faiman & Ryan (1967) 
Midgley & Jaffe (1968) 
Wide et al. (1968) 
Yenetal. (1968) 
Rizkallah et al. (1969) 
following delivery 
following delivery 
following delivery/abortion 
i.v. injection m humans 
following delivery 
i.v. injection in humans 
bioassay 
bioassay 
radioimmunoassay 
bioassay 
radioimmunoassay 
radioimmunoassay 
radioimmunoassay 
3.5 
11 0 
8.9 
8 6 
7.4 
11 0 
5.4 
Parlow & Ward (1961 ) i.v. injection in rats bioassay 4.9 
TABLE III. Plasma disappearance rate of LH 
Author 
Parlow (1965) 
Schalchetal. (1968) 
Kohier et al. (1968) 
Y e n e t a l . (1968) 
Parlow & Ward (1961) 
Gay & Bogdanove ( 1968) 
LH species 
human 
human 
human 
human 
ovine 
murine 
ovine 
murine 
Experimental design 
i.v. injection in humans 
ι v. injection in humans 
i.v. injection in humans 
following hypophysectomy 
¡ v. injection m rats 
i.v. injection in rats 
i.v. injection in rats 
following hypophysectomy 
Assay method 
bioassay 
radioactivity ( 131 l-HLH) 
radioactivity! I31 l-HLH) 
radioimmunoassay 
bioassay 
bioassay 
bioassay 
bioassay 
T' /^mm) 
60 
69 
30-60 
21 
15 
17 
25 
32 
V.Sialic acid and the biologic activity of HCG and L H : 
Removal of sialic acid (desialylation) has been reported to reduce markedly the biologic 
act ivi ty of HCG (for references see the first paper m this thesis). The effect of desialylation 
on the biologic act ivi ty of LH has only been investigated by Adams-Mayne et al. (1964). 
They found no change m biologic activi ty which however is not surprising as they used 
an ovine LH preparation which has an extremely low sialic acid content (0 .3 o /o ) . 
V I . Conclusions: 
From the preceedmg review of the literature the fol lowing conclusions can be drawn 
that are relevant to the studies described m this thesis: 
1. the most important chemical difference between HCG and LH lies m the sialic acid 
content (HCG: 9 % , human L H : 1 . 7 % , ovine L H : 0 . 3 % ) . 
2. the most important biological difference between HCG and LH lies in the plasma 
circulatory half-life (HCG: 3-11 hours, human L H . 20-60 minutes, ovine L H : 15-30 
minutes). 
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3. Preparations w i t h a long Т ' / г (as HCG) have equal biological activity when measured 
by O A A D or VPW. Preparations w i t h a short T ' / Î (as ovine LH) have a considerably 
lower biological act ivi ty when measured by VPW than by O A A D . 
In view of the foregoing the purpose of our first two studies has been to investigate 
whether desialylation of HCG affects its biological activi ty equally when measured 
by O A A D and VPW assays and whether the loss in biological activi ty could be related 
to changes m plasma half-l i fe. The purpose of the last study was to investigate whether 
an L H preparation w i th a higher sialic content than ovine LH could be affected by 
desialylation. 
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Immunological and Biological Activity of 
HCG Following Progressive Desialylation 
EYLARD V. VAN HALL,1 JUDITH L. VAITUKAITIS, AND 
GRIFF T. ROSS, 
Reproduction Research Branch, National Institute of Child Health and Human Development, 
AND JEAN W. HICKMAN AND GILBERT ASHWELL, 
Laboratory of Biochemistry and Metabolism, National Institute of Arthritis and Metabolic Diseases, National 
Institutes of Health, Bethesda, Maryland 20014 
ABSTRACT. The effects of progressive removal 
of sialic acid (desialylation) on the immunological 
and biological activity of HCG, as measured by 
radioimmunoassay (RIA), ovarian ascorbic acid 
depletion assay (OAAD) and ventral prostate 
weight assay (VPW), have been evaluated. Two 
highly purified HCG preparations with poten­
cies of about 12,000 lU/mg (bioassay, 2nd Int. 
Std. HCG) and about 5000 lU/mg (immunoas­
say, 2nd Int. Std. HCG), were used in these 
studies. Progressive desialylation was achieved 
by treating the HCG with varying amounts of 
Clostridium perfnngens neuraminidase. Desialy­
lation did not affect immunological activity. 
Progressive desialylation up to 25% reduced bio­
logical activity by approximately 75% as mea­
sured by OAAD and VPW. Desialylation from 
25 to 62% reduced biological activity further, 
the reduction being much more pronounced when 
measured by VPW than by OAAD, resulting in a 
considerable increase in the index of discrimina­
tion OAAD/VPW. Desialylation from 62 to 
100% did not affect biological activity further, 
giving preparations with a low but significant 
biological potency with an index of discrimina­
tion OAAD/VPW of around 50. {Endocrinology 
88: 456, 1971) 
TREATMENT of human chorionic go­nadotropin (HCG) with neuraminidase, 
an enzyme which specifically removes sialic 
acid residues from the molecule, has been 
reported to reduce markedly, or even to 
destroy, the biological activity of the hor­
mone (1-6) without affecting immuno­
logical activity (5-7). In general, such 
studies have led to the conclusion that 
sialic acid (N-acetylneuraminic acid, 
NANA) is essential for the biological ac­
tivity of HCG. We have briefly reported 
(8) that complete removal of NANA, de­
sialylation, reduced but did not abolish the 
biological activity of HCG, and that the 
degree of reduction depended on the method 
of bioassay but not on the specific activity 
of the starting materials used. 
Received August 13,1970. 
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T h e p u r p o s e of t h i s s t u d y w a s t o inves­
t i g a t e t h e effects of progress ive desialyla­
t i o n o n i m m u n o l o g i c a l a n d biological ac­
t i v i t y of h igh ly purified H C G . 
M a t e r i a l s and M e t h o d s 
Purification of HCG. T h e purification proce­
dures used have been described previously 
(9-11). An initial chromatography with either 
DEAE-Sephadex (9) or DEAE-cellulose (10) 
was performed, with a subsequent purification 
on CM-Sephadex (11). Biological potencies of 
the intermediate and final products were deter­
mined by the mouse uterine weight assay (12) 
and the ovarian ascorbic acid depletion assay 
(13), respectively, and are summarized in 
Table 1. Eluates from the columns were mon­
itored for protein content by measuring ab-
sorbance at 282 τημ with the Uvicord I I of 
L K B , and for immunoreactivity by a hema-
glutination inhibition reaction for H C G (Preg-
nosticon, Organon). T h e pooled fractions were 
dialyzed free of salt and lyophilized. 
Preparation of an anti-neuraminidase-sepharose 
column. An emulsion of C. perfringens neur­
aminidase (500 mg), 0 .9% NaCl, and complete 
Freund's adjuvant (DIFCO) was injected sub-
458 
17 
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TABLE 1. Purification of human chorionic gonadotropin 
Fraction 
Starting material1 
DEAE-Sephadex 
CM-Sephadex 
Starting material 
DEAE-Sephadex 
CM-Sephadex 
Amount (g) 
1 96 
0 48 
0 168 
1.50 
0 81 
0 25 
SA (IU/mg) 
2,270 
6,750 2 
13,500 ' 
2,270 
5,000 ' 
11,290 ' 
Yield (%) 
100 
74 
51 
100 
100 
83 
Code name 
6-CMS-P4 
rri-CMS-P4 
1
 HCG, Lot 91290, Organon, Inc., West Orange, N. J. 
2
 Mouse uterine weight assay, as described in reference (15). 
1
 Ovarian ascorbic acid depletion assay (18). 
cutaneoulsy a t 10-day intervals into each of 6 
adul t female New Zealand white rabbits. T e n 
days after the third injection t h e rabbits were 
bled by cardiac puncture and the antisera col­
lected. T h e potency of t h e antisera was ascer­
tained by incubating varying amounts with 
50 μg of neuraminidase in buffered saline, p H 
7.0, for 60 min a t 37 C. After being stored over­
night a t 3 C, t h e samples were centrifuged and 
t h e supernatant removed for determination of 
residual neuraminidase activity. This was ac­
complished by measuring the amount of NANA 
released in 60 min at 37 С from 1.0 mg of an 
a ^glycoprotein. 
T h e anti-neuraminidase-sepharose column 
was prepared by conjugating the gamma-glob­
ulin fraction, prepared from 4.0 ml of the anti­
serum (14), to activated sepharose (15). T h e 
column (1.5 Х І 0 cm) was then checked for its 
ability t o bind neuraminidase and a capacity of 
0.5 mg С. perfringens neuraminidase found. 
T h e column was regenerated by washing with 
50 ml of 6 M guanidine-HCl, p H 3.0, followed 
by buffered saline T h e column has been used 
repeatedly over 6 months without appreciable 
loss of activity. When not in use the gel was 
stored a t 3 С in t h e presence of 0 .2% sodium 
azide. 
Desialylation Analysis for N A N A was made by 
the thiobarbituric acid method of Warren (16). 
Determination of total protein bound N A N A 
was carried out after acid digestion with O . I N 
H ,S04 a t 80 С for I h r . 
T h e preparation of 70 and 100% desialylated 
H C G was carried out as follows. 500 ßg of 
Clostridium perfringens neuraminidase (Worth-
ington Biochemicals, 1 U mg) was dissolved 
in 1.0 ml of 0 . 5 M acetate buffer, p H 6.3, con-
taining 30 mg of purified HCG. After incuba-
tion for 60 min at 37 С approximately 70 % of 
t h e N A N A had been removed (2.90 дтоіев of 
a total of 3.90 дтоіез) . T o remove t h e residual 
3 0 % t h e sample had to be dialyzed against 1 
liter of 0 . 0 2 5 M acetate buffer and incubated at 
37 С for another hr. At this point, analysis of 
free and total N A N A indicated all of t h e N A N A 
had been liberated (1.024 д т о і е з of a total of 
1.024 дтоіез) . Neuraminidase was completely 
removed from t h e incubation mixture by 
chromatography on a 6 ml column of D E A E -
cellulose equilibrated with 0.05м sodium ace­
ta te . T h e asialo-HCG was not retained on the 
column. 
T h e preparation of partially desialylated 
H C G was accomplished by t h e use of limiting 
amounts of C. perfringens neuraminidase as 
follows. Varying amounts of H C G dissolved in 
1.0 ml of 0 . 0 5 M sodium acetate buffer, p H 5.6, 
were incubated with varying amounts of the 
enzyme. T h e quant i ty of neuraminidase neces­
sary to remove the desired amount of N A N A 
was determined on a preliminary incubation. 
After 20 min, aliquots were removed for the 
determination of free and total N A N A (Table 
2). T h e method of affinity chromatography was 
then employed in order to stop the neuramini­
dase as quickly as possible and remove the 
enzyme from t h e mixture. T h e sample was 
washed onto a column (1.5X10 cm) of anti-
neuraminidase-sepharose with 1.0 ml of buf­
fered saline, p H 7.0. T h e sample was allowed to 
stand 5 min to ensure complete removal of the 
neuraminidase, then eluated with the same 
buffer. 1.0 ml fractions were collected and mon­
itored at 280 πιμ with a Beekman D U spectro­
photometer. Fractions eluated between 3 and 
10 ml containing the partially desialylated 
H C G were pooled, dialyzed and lyophilized. 
Immunoassay. Immunologic activity was de­
termined by a double antibody radioimmuno­
assay (RIA) as previously described for human 
luteinizing hormone (HLH) (17), using H L H -
1 3 1 I as a trace and HCG-antissrum in a final 
dilution of 1:2,500,000 as antibody. A com­
mercial preparation of H C G (Pregnyl, Organon) 
previously assayed against the 2nd Interna­
tional Standard for H C G , was used as a reference 
preparation. Complete dose-response curves 
18 
458 
Incuba­
tion 
(min) 
20 
20 
20 
20 
20 
20 
20 
VJ УМ I 
TABLE 2. Preparation 
Neuraminidase 
added ( 
— 
5 
10 
20 
50 
500 
¿g) 
HCG treated 
(mg) 
10.4' 
16.2' 
19.9' 
19 5' 
11.22 
21.5S 
23.12 
ÍATJ, ET . AL. 
of partially desialylated HCG 
HCG recovered 
(mg) 
8.7 
14.9 
18.0 
17.5 
9 .4 
17.9 
20.0 
Free NANA 
(^moles) 
0.0 
0 35 
0.74 
1 435 
0 . 0 
2.56 
3 63 
Total NANA 
- -
(jumóles) 
2 64 
5.12 
5.74 
5.64 
2.85 
5.48 
5.78 
Volume 88 
Desialyla-
tion 
% 
0 
7 
13 
25 
0 
47 
62 
6-CMS-P4. 2 III-CMS-P4. 
were run for all preparations, with 4 replicates 
at each dose level. 
Bioassays. Two methods were used for mea-
suring biological activity. For the ovarian as-
corbic acid depletion assay (OAAD) of Parlow 
(13) immature female Sprague-Dawley type 
rats, 22 days old and weighing 40-50 g each 
when delivered to the laboratory, were ob-
tained from a commercial source (Holtzmann 
Company, Madison, Wis.). After 3 days a sc 
injection of pregnant mitre serum gonadotropin 
(Equinex, Ayerst), 50 U/animal, was given, 
followed 65 hr later by an injection of human 
chorionic gonadotropin (Pregnyl, Organon), 
25 U/animal. Animals were used for the assay 
3-6 days after the injection of HCG. Test 
materials were diluted with 1 % bovine serum 
albumin in 0.9% NaCl solution (BSA) such 
that each animal received its total dose in 1 ml 
of solution, injected iv per tail vein. Four hr 
later the left ovary was removed, trimmed, 
weighed on a torsion balance, and immediately 
homogenized in 2.5% metaphosphoric acid 
Ascorbic acid was determined by the method of 
Mindlin and Butler (18), using a Coleman Jr. 
colorimeter, find the results expressed in μg/100 
mg of ovarian tissue. After 48 hr the animals 
were used for a second assay and the remaining 
ovary removed. Hypophysectomized immature 
male rats were used for the ventral prostate 
weight assay (VPW) of Greep (19) as modified 
by McArthur (20). Immature Sprague-Dawley 
type rats (Hormone Assay Laboratories, Chi­
cago, 111.) weighing 40-50 g each were delivered 
3 days after hypophysectomy, at which time 
injections were begun. Test materials were di­
luted with 1% BSA so that each animal re­
ceived its total dose in a total volume of 4 cc. 
Of this, 1 cc was given in a single injection on 
the afternoon of the first day and 0.5 cc in­
jected in the morning and afternoon of the 2nd, 
3rd and 4th days. Autopsy was performed on 
the morning of the 5th day and the ventral 
]oh«» o f t h p pro4tat i» япН О П Р tpatiH ГРГПО РГ) a n d 
weighed on a torsion balance. In both assays 
5 animals were used at each dose and the de­
sign was either 2 X2, 3 X2 or 3 X3. BSA-in-
jected controls were included in each assay. 
The 2nd International Standard for HCG was 
used as a reference preparation in most in­
stances but in some assays the starting (fully 
sialylated) preparation was used for this pur­
pose. 
Statistical evaluation. In all 3 assays evaluation 
of parallelism of linear dose-respone curves and 
calculation of relative potency estimates and 
95% confidence limits of these were carried out 
following the method of Brownlee (21). Calcu­
lation of mean potencies and their 95% con­
fidence limits by combination of the individual 
assays was carried out following the method of 
Finney (22). For all calculations appropriate 
programs, designed for a high speed digital com­
puter, were used. Fig. 1 shows dose-response 
curves of intact HCG and 100% desialylated 
HCG in all 3 assays. Apparent parallelism, con­
firmed by statistical testing, shows the suitabil­
ity of the reference preparations used. Similar 
parallelism was found for all the other prepara­
tions with lesser degrees of desialylation. 
R e s u l t s 
Effect on immunological activity. Table 3 
shows the mean potencies of the fully sialy­
lated and the progressively desialylated 
H C G preparations when activity was mea­
sured by RIA. There is a slight but signifi­
cant difference in the immunologic poten­
cies of the two intact preparations, 6-CMS-
P4 being more active t h a n III-CMS-P4. 
When evaluating the immunological po­
tencies of hormones with varying degrees of 
desialylation, it should be remembered t h a t 
the 7,13 and 2 5 % desialylated preparations 
wprp mfldp from fi-C'MS-P4 whilp thp 47 
19 
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62, 70 and 100% desialylated preparations 
originated from III-CMS-P4. Although 
small differences in immuno-potency were 
observed among the different preparations 
no trend was found, and we concluded from 
these data that progressive desialylation 
resulted in no significant change in im­
munological activity of HCG. 
Effect on biological activity. Tables 4 and 5 
show effects of progressive desialylation on 
the mean potencies of HCG when biological 
activity was measured by OAAD and VPW. 
When measured by the OAAD, 6-CMS-P4 
appeared to be slightly more active than 
III CMS-P4. Although the biological po­
tencies of the fully sialylated preparations 
were approximately equal by both bioassay 
methods, biological potency was greater 
than immuno-potency. Progressive desialy­
lation resulted in a marked and progressive 
reduction of both biological activities until 
62% of NANA had been removed. Beyond 
this point no further decrease in activity 
was obtained. Removal of NANA affected 
potency estimates by OAAD (Table 4) and 
VPW (Table 5) similarly up to 25% de­
sialylation. Further removal of NANA re­
duced the biological activity measured by 
VPW more than by OAAD, so that the in­
dex of discrimination OAAD /VPW in­
creased. The differences in potency esti­
mates obtained by bio- and immunoassays 
as reflected by changes in the indices of 
discrimination are shown in Table 6. Effects 
of progressive removal of NANA on the 
biological and immunological activities of 
HCG expressed as per cent residual activity 
adjusted for differences in potency of the 
starting materials are shown graphically in 
Fig. 2. Results may be summarized as fol­
lows: 
1. Draialylation of HCG did not affect its immuno­
logical activity. 
2. Progressive desialylation of HCG up to 25% re­
sulted in progressive and equal decrements in its 
biological activity whether measured by OAAD or 
VPW. 
3. Desialylation of HCG from 25 to 62% reduced 
biological activity further, and this reduction was 
much more pronounced when measured by VPW 
OAAD Ι/2β/70 
Controls BSA 1 % 
л
 Ref prrp 
100% osmio-HCG 
_Ι_^_ί^±_ 
2 0 
IU HCG 
_ 4 0 
E 
ш 
* 
ш 
ьго 
- VPW г/6/70 
-t^ 
^-^^Р<ООІ 
S / * 
s* y 
s s 
L ' S 
Zndlnl Sld HCG 
•^ίθΟ% osmio-HCG 
Controls BSA 1 % 
Ι ι , r , 1 , 1 1 , 1 , 1 
0 3 0.9 
I U HCG 
RIA 5 / 1 4 / T O 
ft Prtgnyl STD 
• 100% asialo-HC6 
0 75 15 3 0 
mlU OF HCG/TUBE 
F I G . 1. Parallelism of dose-response curves of 100% 
asialo-HCG in OAAD, VPW and radioimmunoas­
says. The dilutions of 100% asialo-HCG were made 
such that a linear dose-response curve was obtained. 
The apparent superimposition of the different 
curves is not an expression of equal potency but of 
the dilution chosen. 
than by OAAD, resulting in an increase in the index 
of discrimination OAAD/VPW. 
4. Further desialylation of HCG from 62 to 100 % 
did not affect its biological activity, giving prepara­
tions with low but significant biological ' potency 
with an index of discrimination OAAD/VPW of 
around 50. 
20 
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TABLE 3. Effect of desialylation on immunological activity as measured by RIA' 
Preparation ^ f Ä f 
5820 
6-CMS-P4 (5650-6000 
4430 
III-CMS-P4 (4150-4730) 
5520 
7% Desialylated (5270-5770) 
5270 
13% Desialylated (5030-5510) 
6160 
25% Desialylated (5870-6480) 
6020 
47% Desialylated (5730-6320) 
4140 
6 2 % Desialylated (3900-4400) 
4110 
7 0 % Desmlylated (3850-4380) 
4830 
100% Desialylated (4600-5070) 
1
 Data obtained by combination of individual 
Discussion 
N R 
assays 
3 
2 
3 
2 
2 
1 
2 
2 
2 
Mean g value 
0 0004 
0 002 
0 0008 
0 0008 
0 0009 
0 001 
0 002 
0 002 
0.0009 
Comi 
assays following method of Finney (21). 
correlations between bi ologica 
bined variance 
0 004 
0 03 
0 01 
0 01 
0 01 
0 01 
0 01 
0 01 
0 01 
il activity and 
Effect of desialylation on immunological 
activity. The results of these studies confirm 
the findings of other investigators (5-7) 
supporting Mori's concept that the carbo-
hydrate moiety of HCG is not essential to 
its antigenic activity (6). The observed dis-
crepancy between the immunological and 
biological potencies of the highly purified 
HCG preparations has also been found by 
Schuurs et al. (7) and Wilde (23). These 
investigators attained high biological ac-
tivities of about 19,000 ITJ/mg during puri-
fication of HCG, while immunological po-
tency of about 5000 IU/mg was achieved. 
The increase in biological potency obtained 
by Schuurs et al. (7) was correlated with an 
increase in NANA content. I t seems that 
during the purification of HCG biological 
and immunological potencies increase 
equally to a level of about 5000 lU/mg, 
after which only biological potency and 
NANA content increase further. 
Effect on biological activity. In interpreting 
our results it should be understood'that the 
desialylation are entirely empiric and 
neither specific distribution nor specific se-
quence of desialylation is implied. The ef-
fect of desialylation on the biological activi-
ties of HCG presented two interesting 
features. First, maximal reduction in ac-
tivity was achieved at approximately 60% 
desialylation. This observation suggests 
that the residual activity was not related to 
remaining intact HCG molecules, since 
then progressive decline in biological activ-
ity would be expected as NANA removal 
increased from 62 to 100%. Second, com-
plete desialylation of HCG appeared to 
reduce but not to abolish its biological 
activity, the residual activity being approxi-
mately 50 times higher when measured by 
OAAD than by VPW. This latter observa-
tion further supported the concept that 
residual activity was not caused by the 
remaining fully sialylated HCG molecules, 
in which case no differences in potency esti-
mates would have been expected. Persis-
tence of some biological activity after re-
moval of NANA is not surprising since 
21 
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TABLE 4. Effect of desialylation on biological activity as measured by OAAD1 
461 
Preparation 
6-CMS-P4 
III-CMS-P4 
7% Desialylated 
13% Desialylated 
25% Desialylated 
47% Desialylated 
62% Desialylated 
70% Desialylated 
100% Desialylated 
Potency (lU/mg) 
(95% fid. lim.) 
13,500 
(11,370-16,170) 
11,290 
(9,190-13,660) 
7,210 
(5,770-9,150) 
5,510 
(4,290-7,320) 
2,990 
(2,240-4,160) 
1,250 
(830-2,070) 
60 
(44-83) 
86 
(67-111) 
56 
(42-73) 
NR 
assays 
8 
4 
3 
3 
3 
2 
2 
2 
3 
Mean g value 
0 01 
0.01 
0 02 
0 04 
0 05 
0 06 
0 05 
0 03 
0 03 
Combined variance 
21 275 
11 237 
24.506 
28.782 
33 693 
21 665 
22 790 
16 485 
26 997 
1
 Data obtained by combination of individual assays following method of Finney (21). 
ovine luteinizing hormone, which has an 
extremely low NANA content, has biological 
activities very similar to those of asialo-
HCG. Potency estimates of biological ac­
tivity of ovine LH also differ when mea­
sured by OAAD and VPW and are not 
affected by treatment with neuraminidase 
(24). 
Apparent discrepancies between results 
of our studies and those of similar investi­
gations reported in the literature require 
critical consideration. As early as 1948, 
Whitten (1) reported that serum gonado­
tropin and urinary chorionic gonadotropin 
were rapidly inactivated by influenza virus 
and receptor-destroying enzyme (RDE) 
preparations. In this study biological ac­
tivity was determined by measuring rat 
ovarian weight 120 hours after a single in­
jection of the test material at one dose 
level, so that residual activity might have 
been observed if larger doses had been 
given. 
Brossmer and Walter (2), using the VPW 
assay for measuring biological activity, 
found a 555-fold decrease in activity after 
treatment of HCG with influenza virus and 
RDE and recognized the active principle 
in these preparations to be neuraminidase. 
They emphasized that a small but signifi­
cant activity was observed in all their 
preparations after exposure to the enzyme. 
Rafelson etat. (4) reported that "removal 
of sialic acid totally destroyed the biological 
activity as estimated by the ovarian weight 
in immature rats." This conclusion was 
based on results of a single assay and ex­
amination of their data suggests that, 
whereas 60.6 μg of the treated gonadotropin 
had a potency of less than 10 IU, residual 
activity may have been present. 
Schumacher et al. (3) investigated the 
correlation between time of incubation with 
fixed amounts of neuraminidase and the 
release of NANA, and the effects on the 
biological activity of HCG. They found 
that a release of 15% NANA resulted in a 
50% reduction in biological activity, as 
measured by the mouse uterine weight 
assay, whereas 20 to 30% desialylation al­
most completely inactivated the hormone. 
These data suggest a greater reduction in 
22 
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TABLE 5. Effect of desialylation ou biological activity as measured by VPW1 
Preparation Potency (lU/mg) NR (95% fid. lim.) assays Mean g value Combined variance 
6-CMS-P4 
III-CMS-P4 
7% Desialylated 
13% Desialylated 
25% Desialylated 
47% Desialylated 
62% Desialylated 
70% Desialylated 
100% Desialylated 
11,110 
(9,930-13,220) 
(10 
(5 
(3 
(1 
11,740 
,050-13,670) 
7,390 
,570-9,880) 
5,070 
,260-7,760) 
2,800 
,940-3,990) 
220 
(150-300) 
1.3 
(0.9-1.8) 
0.7 
(0.4-1.1) 
1.2 
(0.9-1.6) 
8 
7 
4 
2 
3 
2 
3 
1 
4 
0.01 
0.01 
0.02 
0.05 
0.03 
0 03 
0.04 
0.07 
0.03 
33.413 
41.969 
51.603 
41 875 
47.118 
37 354 
44.307 
19.552 
35.04 
1
 Data obtained by combination of individual assays following method of Finney (21). 
potency for comparable degrees of desialy- sibility of differences relating to the method 
lation than we observed (see Fig. 2). This of biological assay cannot be excluded 
may have resulted from failure to remove completely. 
the neuraminidase from the gonadotropin Barr and Collée (5) also studied the in-
so that after thawing further desialylation fluence of the amount of NANA removed 
may have occurred. In addition, the pos- upon the biological activity of HCG. Their 
TABLE 6. Effect of desialylation on indices of discrimination (I.D.) for biological and immunological 
potency estimates 
Preparation 
6-CMS-P4 
III-CMS-P4 
7% Desialylated 
13% Desialylated 
25% Desialylated 
47% Desialylated 
62% Desialylated 
70% Desialylated 
100% Desialylated 
Potency 
OAAD 
13,500 
11,290 
7,210 
5,510 
2,990 
1,250 
60 
86 
56 
Potency 
VPW 
11,110 
11,740 
7,390 
5,070 
2,800 
220 
1.3 
0 . 7 
1.2 
Potency 
RIA 
6,820 
4,430 
5,520 
5,270 
6,160 
6,020 
4,140 
4,110 
4,830 
I.D. 
OAAD/VPW 
1.2 
1.0 
1 .0 
1.1 
1.1 
5 . 7 
46 
118 
47 
I.D. 
в vi2 
2 . 3 
2 .6 
1.3 
1 1 
0 . 5 
0 . 2 
0.02 
0.02 
0.01 
' Biological potency as measured by OAAD. 
• Immunological potency as measured by RIA. 
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J 1 I I 1 I t I I 1 _ 
10 2 0 30 «O 50 60 70 80 »O IOO 
PERCENT NANA REMOVED 
FIG. 2. Effect of progressive desialylation on im-
munological (RIA) and biological (OAAD, VPW) 
activity of HCG. 
data show that there is a residual activity of 
18%, as measured by the spermiation re-
sponse of the male Xenopus laevis after 78 % 
desialylation. This represents a consider-
ably higher residual activity than we found 
in these studies, but accurate estimates of 
the amount of NANA released from HCG 
in the experiments of Barr and Collée are 
difficult, since the HCG preparation had a 
biological activity of only 2000 lU/mg and 
contained other sialoproteins. 
In a recently published study on the anti-
genic structure of HCG, Mori (6), using a 
seminal vesicle weight bioassay, measured 
biological activity of highly purified HCG 
at varying times after exposure to neur-
aminidase. After 80 minutes of incubation 
with a fixed amount of enzyme, there was 
still a considerable residual activity of 41 %. 
Although he reported that incubation for a 
period of 60 minutes in another experiment 
removed approximately 40% of NANA, no 
NANA determinations were made during 
the time studies, making it difficult to 
interpret his data in the light of our studies. 
In summarizing the results of previous 
investigations relating desialylation to bio-
TABLE 7. Correlation between NANA content 
and the circulatory half-life of gonadotropins 
HCG 
HCG 
FSH 
LH 
(human) 
LH 
(ovine) 
NANA 
(% dry weight) 
9.81 
8.0» 
5.2' 
1.4' 
0.3» 
Τ 
(min) 
660» 
480' 
360« 
65· 
IS1 0 
' Potency 18,800 lU/mg (7). 
> Endogenous HCG (26), included in table on the 
assumption that endogenous HCG is comparable 
to highly purified HCG. 
» Potency 7900 lU/mg (27). 
4
 Potency 7900 lU/mg (28). 
1
 Potency 137XN1H-FSH-S1 (29). 
•"Purified" (30). 
7
 Potency not mentioned (25). 
• Potency not mentioned (25). 
• Potency 2.50 XNIH-LH-Sl (31). 
10
 Potency not mentioned (25). 
logical activity of HCG, several points 
should be emphasized. First, bioassays used 
in all studies except one (5) depended on 
"chronic" target organ weight responses 
such as mouse uterine weight (3), rat ovari­
an weight (1, 4), ventral prostate weight 
(2) and seminal vesicle weight (6). In the 
only study where a more acute response, 
the spermiation of the male Xenopus laevis, 
was used for evaluation of biological activ­
ity, significant residual activity was found 
after as much as 78 % desialylation. Second, 
in those studies where desialylation of HCG 
was reported to destroy biological activity 
(1, 3, 4), experimental design did not ex­
clude the possibility of small amounts of 
residual activity. 
Finally, the increasing discrepancy be­
tween biological potency estimates as mea­
sured by OAAD and VPW after 25% de­
sialylation merita consideration. Parlow 
(25) has correlated changes in the relative 
potencies of various preparations of LH, 
when measured in OAAD and VPW assays, 
with the plasma half-life of these substances. 
In general, preparations with shorter half-
lives had higher relative potencies in the 
OAAD than in the VPW assay. In other 
words, the index of descrimination OAAD/ 
VPW increased as the plasma half-life 
24 
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decreased. In addition, there seems to be 
a correlation between the NANA content 
and the plasma half-life of gonadotropins 
(see Table 7). Furthermore, desialylation 
of another glycoprotein, ceruloplasmin, has 
been demonstrated to result in its prompt 
removal from the circulation and concomi-
tant accumulation in the liver (32), sug-
gesting that NANA plays an important 
role in the rate of metabolism of some 
glycoproteins. 
Reichert (33) has shown that indices of 
discrimination varied significantly from 
unity when a series of LH preparations were 
assayed by OAAD and ovarian hyperemia 
assays. Since both these assays depend upon 
"acute" responses, it seems likely that dif-
ferences in plasma half-life are not the sole 
explanation for the differences in potencies 
observed. Nevertheless, our observations, 
and those of others discussed above, lead us 
to suggest that desialylation of HCG in-
creases its rate of clearance from plasma, 
resulting in a reduction in biological activ-
ity. Since this phenomenon would be ex-
pected to have a larger effect on bioassays 
depending on a growth response, bioassays 
such as the VPW would be affected more 
than those depending upon an acute bio-
chemical response such as OAAD. In fact, 
progressive desialylation was accompanied 
by an increase of the index of discrimination 
OAAD/VPW. 
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Effects of Progressive Desialylation on the Rate of 
Disappearance of Immunere active HCG from Plasma in Rats 
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ABSTRACT. A specific radioimmunoassay was 
used to measure concentrations of immuno-
reactive hormone in plasma samples taken at in­
tervals following injection of intact and variably 
desialylated preparations of highly purified hu­
man chorionic gonadotropin (HCG) into pseudo-
pregnant rats. Desialylation of HCG up to 25% 
decreased plasma half-life by 50% (from 25 to 
11 min). Removal of sialic acid over the range of 
25-62% resulted in a more profound reduction in 
plasma tj (from 11 to less than 1 min) but 
desialylation greater than 62 % was without addi­
tional effect. The observations suggest that pre­
viously observed deorements in biologic activ'ty 
following progressive desialylation of HCG re­
sult, in part, from changes in plasma half-life of 
the hormone. {Endocrinology 89 : 11, 1971) 
WE HAVE reported that progressive desialylation of human chorionic go­
nadotropin (HCG) markedly reduced its 
biological activity, but the decrease in 
potency was much more pronounced when 
measured by the ventral prostate weight 
assay (VPW) than by the ovarian ascorbic 
acid depletion assay (OAAD) (1). Since 
desialylation of ceruloplasmin and other 
glycoproteins had been shown to cause 
increased clearance of these substances 
from plasma (2, 3), we suggested that this 
reduction in biological activity of HCG and 
the discrepancy in potencies observed in 
the two assays could be related to an in­
creased rate of disappearance of the hor­
mone from the circulation (1, 3). 
The purpose of this study was to deter­
mine whether, in fact, progressive desialyla­
tion decreased the plasma half-life of HCG 
in a fashion similar to that shown for 
ceruloplasmin and other glycoproteins. 
Received December 23, 1970. 
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M a t e r i a l s and M e t h o d s 
Purification and desialylation of HCG. T h e 
methods of purification and desialylation have 
been extensively described and t h e preparations 
used in t h e present experiments were t h e same 
as those used in our previous studies (1). 
Experimental design. T h e experiments were per­
formed on pseudopregnant immature female 
Sprague-Dawley t y p e ra t s during t h e period 
when these animals were most suitable for t h e 
OAAD assay (1). T h e animals were divided in 
groups of 5 and each received a single injection 
per tail vein of 200 ng of the preparations to be 
tested. At t ime intervals varying from 1 t o 120 
min following injection the animals were anes­
thetized with ether and blood was obtained by 
aortic puncture. T h e blood was collected in 
heparinized tubes, centrifuged, and the plasma 
was stored at —20 С until analyzed. 
Radioimmunoassay. Immunoreactive H C G in 
t h e plasma samples was determined by a double 
antibody radioimmunoassay (RIA) as pre­
viously described for h u m a n luteinizing hor­
mone ( H L H ) , using either l ; , 4-HLH or 1 3 1 I -
H C G as trace and a specific H C G antiserum in 
a final dilution of 1 : 2,500,000 as antibody (4). 
T h e same amount of r a t plasma used for t h e 
samples (200 μ\) was added to t h e control and 
s tandard curve tubes in order to avoid biased 
results due to eventual interference of t h e r a t 
plasma with t h e second antibody reaction (5). 
As shown in Fig. 1, the addition of ra t plasma 
11 
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F I G . 1. Effects of addition of 200 μ\ of rat plasma 
on immunopotency of HCG: # — # Standard dis­
solved in buffer, buffer only in control tubes; 
•—Щ standard dissolved in rat plasma with buffer 
only in control tubes; О—О standard dissolved in 
rat plasma with rat plasma in control tubes. 
indeed affected t h e slope of t h e s tandard curve 
when measured in terms of controls (0 and 100 % 
tubes) in buffer only; when r a t plasma was 
added also t o t h e control tubes, however, t h e 2 
s tandard curves were indistinguishable from 
each other. 
T h e percentage of t h e injected dose present 
in 1 ml of plasma was calculated on t h e basis of 
previously established immunopotencies of t h e 
different preparations (1). T h e plasma half-lives 
(tj) were estimated from a semilogarithmic plot 
of means of these values against t ime. 
Results 
Disappearance of intact HCG. After injec­
tion of intact HCG, plasma immunoreac-
tivity decreased multiexponentially with an 
initial tj of approximately 20 minutes 
(Fig. 2). When the pseudopregnant rats 
were oophorectomized just prior to the 
injection of HCG, the disappearance rate 
was substantially slower, with an initial 
tj of approximately 70 minutes (Fig. 2). 
Disappearance of desialylated HCG. Pro­
gressive removal of sialic acid indeed 
increased the rate of removal of HCG from 
plasma (Table 1; Fig. 3). Up to 25% 
desialylation, the initial tj was reduced 
60 120 ISO 240 180 
TIME (mlnum) 
F I G . 2. Curves of disappearance of HCG from 
plasma of pseudopregnant rats: Intact φ — φ and 
О—О; oophorectomized A—•• 
from 20 to 10 minutes. At 47% desialyla­
tion, however, there was a dramatic change 
in the disappearance rate, resulting in an 
initial t} of approximately two minutes. 
The disappearance curves for the 62 and 
100% desialylated preparations were in­
distinguishable from each other, the tj 
being less than one minute in both instances 
(Table 1; Fig. 3). 
In view of the observed difference in 
disappearance rate for intact HCG in the 
oophorectomized and intact animals, it was 
necessary to exclude the possibility that the 
rapid disappearance of asialo-HCG was 
caused by gonadal rather than extragonadal 
factors. Therefore, the disappearance rates 
of 100% desialylated HCG were compared 
in intact and oophorectomized rats and, in 
order to assure measurable amounts of 
hormone for longer than five minutes, the 
amount of injected material was increased 
from 200 ng to 2 μg. The results of this 
experiment are shown in Fig. 4. Although 
the disappearance rate was slower in the 
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TABLE 1. Plasma concentrations of immunoreactive (asialo) 
HCG at varying time intervals after injection 
Preparation 
III—CMS—P4 
(intact HCG) 
13% Desialyl 
25% Desialyl. 
47% Deeialyl. 
62% Desialyl. 
100% Desialyl 
Immuno 
potency 
IU/mgi 
4430 
5270 
eieo 
6020 
4140 
4860 
1 
— 
— 
— 
50 8 
± 5 4 
27 3 
± 3 7 
17 5 
±7 1 
MIU' (asíalo) HCG/ml plasma ± SE at time (in 
3 
— 
— 
— 
37 2 
± 4 . 6 
4 3 
± 2 1 
6 6 
± 0 4 
5 
99 0 
± 4 4 
112 0 
± 5 1 
104 β 
± 4 9 
16 3 
± 1 5 
1 8 
± 0 2 
3.1 
± 0 β 
10 
78 5 
± 3 8 
108 0 
± 5 9 
82 β 
± 8 3 
2.9 
± 0 1 
— 
20 
60 6 
± 4 8 
82 2 
± 3 2 
43 0 
± 2 4 
1 6 
± 0 1 
— 
30 
45 6 
± 3 5 
50 0 
± 6 1 
27 9 
± 4 0 
— 
— 
45 
35 3 
± 5 β 
31 4 
± 3 0 
12 5 
± 1 5 
— 
— 
~ 
min) after injection 
60 
18 7 
± 1 0 
18 5 
± 0 8 
14 2 
± 3 5 
— 
— 
~ 
90 
8 3 
± 1 9 
7 5 
± 1 β 
5 5 
± 1 1 
— 
— 
" 
102 
7 8 
± 1 3 
6 1 
± 1 0 
3 β 
± 0 4 
— 
— 
(mm) 
25 
21 
11 
2 
< 1 
< 1 
« As determined by RIA (1) 
1
 Means of individual determinations in the rats of each group. 
1
 Estimated from a semiloganthmic plot of % injected dose/ml plasma against time. 
oophorectomized animals, consistent with 
some binding of the asialo-HCG to the 
ovaries in the intact animals, it is obvious 
that clearance must be primarily extra-
gonadal. 
Discussion 
The results of our studies may be 
summarized as follows: 
1. Desialylation of HCG up to 2 5 % resulted in a 
2-fold decrease in its initial plasma half-life. 
2. Desialylation of HCG from 25 to 62% resulted 
in a more marked decrement in its plasma half-life. 
3. Desialylation of HCG from 62 to 100% did not 
result in detectable further change in its plasma 
half-life. 
The differences between plasma half-
lives of HCG in intact and oophorectomized 
pseudopregnant rats suggest that the 
ovaries of pseudopregnant rats, being 
heavily luteinized and weighing approx-
Plasma 7"4 
F I G . 3. Curves of disappear­
ance of variably desialylated 
preparations of HCG from 
plasma following injection 
into pseudopregnant rats: 
· — · Intact HCG; D — D 
1 3 % desialylated HCG; 
О — О 25 % desialylated 
HCG; Δ — Δ 47% desial­
ylated HCG; • - • 62% 
desialylated HCG; A — A 
100% desialylated HCG. 
50 6 0 70 
TIME (minutes) 
100 110 120 
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imately ten times more than the ovaries of 
untreated animals of the same age, are 
able to remove relatively larger amounts of 
HCG from the circulation. This is in 
agreement with the findings of Beals and 
Midgley (6), who showed that pseudo-
pregnant rat ovaries could bind up to 50% 
of an injected dose of 13II-labeled HCG. 
Still, the t j in our oophorectomized pseudo-
pregnant rats is somewhat lower than the 
value of 5.3 hours found by Parlow and 
Ward (7) in mature female rats. I t does not 
seem probable that the hormonal milieu in 
the pseudopregnant rat provides an expla­
nation for the discrepancy in our results 
and those of Parlow since we have found in 
separate studies that the plasma tj of 1 2 5I-
labeled HCG in intact immature female 
rats, not primed with PMS and HCG, was 
the same as that found in the present stud­
ies in the oophorectomized pseudopregnant 
rats. While the basis for this discrepancy 
remains unknown, the short initial tj of 
intact HCG we observed does not alter 
conclusions drawn from our experiments, 
since the data clearly indicate that desialy-
lation of HCG strongly affects its circula­
tory survival. 
It is of interest to correlate these findings 
with the results of our studies concerning 
the effects of progressive deeialylation on 
the biological activity of HCG (1). Our 
studies show that desialylation up to 25% 
produces only a halving of the disappear­
ance rate of HCG. I t is noteworthy that 
over the same range of desialylation the 
loss in biological activity was similar when 
measured by OAAD or VPW assays (1). 
From 25 to 62% desialylation, where the 
further decrease in biological activity is 
accompanied by a progressively increasing 
index of discrimination OAAD/VPW, the 
changes in plasma t 4 are more pronounced, 
consistent with Parlow's findings of a cor­
relation between the plasma half-lives and 
the indices of discrimination OAAD/VPW 
of some LH preparations (8). The finding 
that there is no demonstrable difference 
between the disappearance curves of the 
62 and 100% desialylated preparations, 
coupled with our previous findings that 
after 62% desialylation biological activity 
was not further decreased, serves to fur­
ther emphasize the correlation between 
rate of disappearance from plasma and 
biological activity. I t appears likely that 
with a plasma t j of less than one minute at 
62% desialylation a biological minimum 
has been reached. 
These experiments provide no valid 
explanation for the mechanisms by which 
desialylation affects the disappearance rate 
of HCG. I t is possible that, in common with 
ceruloplasmin and other glycoproteins, ex­
posure of galactosyl residues results in 
prompt removal of the molecule from circu­
lation by the liver (2, 3). However, this 
would not explain the impressive correla­
tion between the plasma half-lives of 
different gonadotropins and their sialic 
30 
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acid content (1), as there is no reason to 
believe that intact gonadotropins have free 
galactosyl residues. I t is reasonable to 
suppose that, as shown for some other 
glycoproteins (9, 10), sialic acid may pro­
tect hormones from some destructive pro­
cess such as degradation by proteolytic 
enzymes. 
The major inference to be drawn from 
our studies is that desialylation of HCG 
increases its plasma disappearance rate, 
thus affecting its delivery to the ovary, and, 
as we tentatively proposed earlier, this 
might well be the major cause of its loss 
of biological activity (1, 3). However, the 
fact that a 50% reduction in plasma tj (up 
to 25 % desialylation) is accompanied by a 
substantial loss of biological activity (ap­
proximately 75%) leads us to believe that, 
in addition to the plasma disappearance, 
other factors such as target-organ re­
sponsiveness, might also be involved. 
References 
1. Van Hall, E. V., J. L. Vaitukaitie, G. T. Ross, 
J. W. Hickman, and G. G. Ashwell, Endocri­
nology 8 8 : 456,1971. 
2. Morel, A. G., R. A. Irvine, I. Stemlieb, I. H. 
Scheinberg, and G. G. Ashwell, J Biol Chem 
2 4 3 : 155, 1968. 
3. Morel, A. G., G. Gregoriadis, I. H. Scheinberg, 
J. Hickman, and G. G. Ashwell, J Biol Chem 
246: 1461, 1971. 
4. Odell, W. D., P. L. Rayford, and G. T. RDSS, 
J Lab Clin Med 70 : 973, 1967. 
5. Burr, I. M., D. B. Grant, P. С Sizonenko, 
S. L. Kaplan, and M. M. Grumbach, J Clin 
Endocr 2 9 : 948, 1969. 
6. Beale, T. F., and A. R. Midgley, Abstracts of 
Papers, Second Annual Meeting, Society for the 
Study of Reproduction, 1969, p. 3. 
7. Parlow, A. F., and D. N. Ward In Albert, A. 
(ed. ), Human Pituitary Gonadotropins, Charles 
С Thomas, Springfield, 111., 1961, p. 204. 
8. Parlow, A. F., In Roeemberg, E. (ed.), Gonado-
trophins, 1968, Geron-X, Inc., Los Gatos, 
Calif., 1968, p. 59. 
9. Yamashina, Ikuo, Acta Chem Scand 10: 1066, 
1956. 
10. Winzler, R. J., In Putnam, F. W. (ed.), The 
Plasma Proteins, Academic Press, New York, 
1960, p. 309. 
31 

Vol. 42, No. 5, 1971 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
THE EFFECTS OF DESIALYLATION ON THE BIOLOGIC AND IMMUNOLOGIC 
ACTIVITY OF HUMAN PITUITARY LUTEINIZING HORMONE 
Glenn D. Braunstein, Leo E. Reichert, Jr.*, Eylard V. Van Hall, Judith L. 
Vaitukaitis, and Griff T. Ross 
Reproduction Research Branch, National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, Maryland 20014, and 
•Department of Biochemistry, Division of Basic Health Sciences, Emory 
University, Atlanta, Georgia 30322 
Received January 25, 1971 
SUMMARY 
A highly purified preparation of human pituitary luteinizing hormone 
was treated with neuraminidase resulting in 94% removal of the sialic acid 
moiety. This led to a marked loss of biologic activity as measured by the 
ventral prostate weight and ovarian ascorbic acid depletion assays, and 
enhancement of the radioimnunologic activity. 
INTRODUCTION 
The biologic activity of human luteinizing hormone (HLH) has been reported 
to be unaffected by removal of sialic acid (desialylation) (1,2), while the 
biologic activity of highly purified human chorionic gonadotropin (HCG) was 
reduced to less than 1% by complete desialylation with neuraminidase (3). We 
attempted to utilize this supposed differential effect of desialylation on 
the biologic activities of the two hormones to discriminate between HCG and 
HLH in urinary extracts thought to contain both. In preliminary experiments 
utilizing crude urinary and pituitary HLH preparations treated with a 
neuraminidase devoid of proteolytic activity, we observed an unexpected 
marked loss of biologic activity. Subsequently, a highly purified pituitary 
HLH preparation was treated with neuraminidase to remove sialic acid and 
the results of biologic and inmunologic assays of the desialylated hormone 
are reported herein. 
MATERIALS AND METHODS1 
HLH Preparations: Partially purified HLH was derived from acetone-dried 
'-The purified HLH was prepared and desialylated in Atlanta, and the biologic 
and radioinmunoassays were performed in Bethesda. 
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human pituitary glands by anmonium sulfate extraction and fractionation, 
followed by ion-exchange chromatography on DEAE-cellulose at pH=8.0 (4). 
A fraction equivalent to F-l-2 of that reported was then rechromatographed 
on DEAE-cellulose in O.IM glycine buffer at pH=9.5 (5), followed by gel 
filtration through Sephadex G-100 (6). The final product, LER 1486-2, was 
used as the starting material for these studies. 
Neuraminidase Preparations: Purified HLH was desialylated with preparations 
of Clostridium perfringens neuraminidase (Sigma Chemical Company, St. Louis, 
Mo.) which was shown to be free of chymotrypsin activity when examined by 
the acetyl-L-tyrosine ethyl ester hydrolysis method of Schwert and Takenaka (7). 
HLH is known to be particularly susceptible to inactivation by this type of 
enzyme (8). The enzymic activity of the neuraminidase was checked prior to 
each hormone digestion using neuramin-lac tose as a substrate. The commercial 
source of the neuraminidase did not influence the percentage of residual 
activity remaining after desialylation of several HLH preparations. 
Desialylation Procedure: 30.05 mgm of LER 1486-2 were dissolved in 0.1M 
acetate buffer, pH=6.1, 0.93 mgm of Ç. perfringens neuraminidase (Sigma, 
Type V, 0.18 units/mgm) added to the hormone solution giving a ratio of 
mgm HLH:units enzyme of 179, and the mixture incubated at 37° for one hour. 
Two samples (LER 1486-2a) containing one milligram of protein were removed 
for N-acetylneuraminic acid (NANA) determination by the Warren method (9). 
The remaining solution was dialyzed and lyophilized (LER 1486-2a^). 
The total recovery was 86% by weight. 
Duplicate determinations of NANA were performed by the Warren procedure (9) 
following incubation of two aliquote containing one milligram of LER 1486-2 
in 0.1 N sulfuric acid for one hour at 80oC. Similar samples of LER 1486-2а^ 
were subjected to the same procedure. 
A second enzyme digestion utilizing Ç. perfringens neuraminidase (Sigma, 
Type VI, 3.5 units/mgm) was performed on 23.38 mgm of LER 1486-2a1 under the 
conditions described above, but with an HLH:units enzyme ratio of 30:1. Again, 
963 
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two one milligram aliquote of the digested material were subjected to NANA 
determinations (LER 1486-2b) and the remaining solution dialyzed and lyophilized 
(LER lUB6-2b1) yielding 827. recovery by weight. The NANA content of the latter 
preparation was determined after sulfuric acid digestion as described above. 
Bioassays: Biologic activity of the hormonal preparations were determined 
using the McArthur modification (10) of the ventral prostate weight assay (VPW) 
of Greep (11) and the ovarian ascorbic acid depletion assay (QAAD) of Parlow (12), 
as previously described (3). Five rats were used at each dose level in 2 χ 2, 
2 x 3 , or 3 χ 3 parallel line graded response assays. Assays were performed 
on aliquota of the same hormone solutions. LER 907, standardized against 
the Second International Reference Preparation of Human Menopausal Gonadotropin, 
was used as the reference preparation in all assays. 
Radloimnunoassays: The double antibody radioinmunoassay for HLH as described 
by Odell, Ross, and Rayford (13) was used with LER 907 serving as the reference 
preparation. 
Statistical Analysis: The methods of Brownlee (14) were applied to each 
Individual assay for evaluation of parallelism of dose-response curves, 
calculation of relative potency, and 957. confidence limits. The method of 
Finney (15) was utilized to calculate the combined mean potencies and 95% 
confidence limits from valid assays. 
RESULTS 
NANA Analysis: Table I sunmarizes the results of NANA determinations made 
on the starting material', LER 1486-2, and the 66% and 94% desialylated 
preparations. It should be noted that the quantity of NANA present in the 
initial preparation, 2.3%, corresponds well with the values obtained by 
others (16-19). 
Bioassays: Preliminary OAAD assays performed in Atlanta (LER) showed no 
significant differences in potency of the 66% and 94% desialylated prepara­
tions, both having residual activity of 15-20%. Table II gives the results 
of four VPW and three QAAD assays of LER 1486-2 and 1486-2b1 performed at 
Bethesda. Aliquote of the same solutions were used In the QAAD and VPW assays. 
964 
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TABLE I 
Summary of NANA Analysis 
Preparation 
NANA1 
Released by 
Sulfuric Acid % NANA2 
Rado 
% NANA1 mgm LH 
Desialy- Released Units 
lation by Enzyme Enzyme 
LER 1486-2 0.074 
(control) 
LER 1486-2a 
(1486-2 after first 
enzyme digestion) 
LER 1486-23! 0.025 
(1486-2a lyophilized 
and submitted to acid 
hydrolysis) 
LER 1486-2b 
(1486-2 after enzyme 
digestion, lyophill-
zation and a second 
enzyme digestion) 
LER 1486-2b1 0.005 
(1486-2b lyophilized) 
2.3 
0.084 
0.78 6631 
0.034 
0.14 94% 
179 
30 
1
 Micromoles of NANA per mgm LH 
2
 Assuming 100% release. Since apparently not all NANA is released, 
this is a minimum figure 
The discrepancy in the potency estimates of HLH as measured in the 0AAD 
and VFW assays has been previously noted, and occurs with several different 
luteinizing hormone preparations from both human and non-human sources (20,21). 
Imnrunoassay: The specific activities of 1.0 nanogram (ng) of LER 1486-2 and 
LER 1486-2b1 were equivalent to 46.0 and 65.8 ng of LER 907 respectively, 
indicating that the imnunoreactivity of HLH was significantly enhanced (143.77. 
residual activity) after 94% desialylation. 
DISCUSSION 
Several points in the present work warrant eoamente. First, significant 
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TABLE I I 
Results of OAAD and VPW Assays of Fully Slalylated and 94% Desialylated Human 
Pituitary Luteinizing Hormone 
Preparation 
Specific Activity (IU/mgm) % Residual 
Assay (95% Confidence Limits) // Assays Activity 
LER 1486-2 OAAD 
(control) 
LER 1486-20! OAAD 
(1486-2 after 
enzyme digestion, 
lyophilized and 
second enzyme 
digestion) 
LER 1486-2 VPW 
LER 1486-2b1 VPW 
3546 
(2528-5525) 
573 
(434-797) 
1910 
(1536-2374) 
238 
(190-293) 
100.0% 
16.2% 
100.0% 
12.5% 
loss of biologic activity occurs after desialylation of HLH by neuraminidase. 
This decreased bioreactivity may be due to increased metabolic clearance of 
the HLH after the removal of sialic acid, as has been shown to occur for HCG, 
follicle stimulating hormone, and other glycoproteins after desialylation (22). 
The reasons for the discrepancy in the amount of biologic activity remaining 
after desialylation reported herein and those previously reported (1,2) are 
not apparent. It is noteworthy that these earlier reports did not include 
measurement of the amount of sialic acid removed. Second, the inminoreactivity 
of HLH, tested by a double antibody method of radioimnunoassay using an 
antiserum made against HCG, is enhanced almost 1^ times by the removal of 
sialic acid. Mori, using complement-fixing techniques did not find similar 
augmentation by desialylation (2), but did find Increased activity of 
chymotrypsin-treated HLH (23). Desialylation of other hormones has yielded 
variable results. The immunoreactivity of desialylated HCG does not change (3), 
while recent studies on human urinary FSH have shown augmentation of inmuno-
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reactivity and loss of biologic activity after desialylation with neuraminidase 
(24). The enhancement of inmunoreactivity of pituitary HLH after the removal 
of sialic acid may be due to the uncovering of immunoreactive sites. Last, 
the divergent potency estimates between the imnunologic and biologic assays 
of multiple purified HLH preparations (25) may be due to partial desialyla­
tion of some of these preparations during their purification. 
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SUMMARY A N D CONCLUSIONS 
In the first paper of this thesis the effects of progressive removal of sialic acid (desialy-
lation) on the immunological and biological activi ty of HCG, as measured by radio-
immunoassay (R IA) , ovarian ascorbic acid depletion assay (OAAD) and ventral pros-
tate weight assay (VPW), have been evaluated. Two highly purif ied HCG preparations 
wi th potencies of about 12,000 lU/mg ( O A A D and VPW) and about 5000 lU /mg 
(R IA) , were used in these studies. Progressive desialylation was achieved by treating the 
HCG wi th varying amounts of Clostr idium perfrmqens neuraminidase. Desialylation did 
not affect immunological act ivi ty. Progressive desialylation up to 2 5 0 / o reduced 
biological activi ty by approximately 75 0 / o as measured by O A A D and VPW. Desialylation 
f rom 25 to 6 2 0 / o reduced biological activi ty further, the reduction being much more 
pronounced when measured by VPW than by O A A D , resulting m a considerable increase 
m the index of discrimination OAAD/VPW. Desialylation f rom 62 to 100 o /o did not 
affect biological act ivi ty further, giving preparations w i th a low but significant biological 
potency w i th an index of discrimination OAAD/VPW of around 50. 
This observed discrepancy between relative potencies measured by O A A D or VPW assays 
after desialylation of HCG led us to suggest that the loss in biologic act ivi ty could be 
related to changes in the plasma-circulatory half-l ife. 
This hypothesis formed the base of the studies reported in the second paper, m which the 
effects of progressive desialylation on the plasma disappearance rate of HCG was inves-
tigated. 
A specific radioimmunoassay was used to measure concentrations of immunoreactive 
hormone m plasma samples taken at intervals fo l lowing injection of intact and variably 
desialylated preparations of highly purif ied Human Chorionic Gonadotropin (HCG) into 
pseudopregnant rats. Desialylation of HCG up to 25 0 / o decreased plasma half-l ife by 
5 0 o / o ( f rom 25 minutes to 11 minutes). Removal of sialic acid over the range of 25 0 /o~ 
6 2 0 / o resulted in a more profound reduction m plasma t1 /2 ( f rom 11 minutes to less 
than 1 minute) but desialylation greater than 6 2 0 / o was wi thout addit ional effect. 
The observations suggest that previously observed decrements m biologic activi ty fo l low-
ing progressive desialylation of HCG result, in part, f rom changes in plasma half-l ife of the 
hormone. 
In the th i rd paper, the effects of desialylation on the biologic and immunologic activi ty 
of human pi tu i tary LH were investigated. A highly purif ied preparation w i th a NANA-
content of 2 . 3 % and a biologic activity of 3546 lU/mg (OAAD) and 1910 l U / m g 
(VPW) was treated w i th neuraminidase resulting in 9 4 0 / o removal of the sialic moiety. 
A marked loss m biologic activi ty was observed, the residual potency being 16.2 0 /o 
m the O A A D and 12.50 /o m the VPW assay. Immunologic act ivi ty was significantly 
enhanced ( 1 4 4 % ) . 
From our studies the fo l lowing conclusions can be drawn: 
Desialylation did not significantly affect the immunologic act ivi ty of HCG but resulted 
m a significant increase of the immunologic activi ty of H L H . A similar effect has been 
recently reported for FSH (Vaitukait is et al., 1971) and might be explained by alteration 
in the tert iary structure of these glycoproteins leading to exposure of previously covered 
antigenic sites. 
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The observed changes in biologic activity lead us t o postulate that desialylation of HCG, 
and by inference of L H , increases their plasma disappearance rate, thus affecting their 
delivery t o the target organ, and that this might well be the major cause of the loss in 
biologic act iv i ty. 
Recent studies (van Hall et al., 1971) on the m vivo and m v i t ro binding of asialo-HCG 
t o rat gonads seem to support this hypothesis. Using a biologically and immunological ly 
active 1 2 5 l-labelled HCG preparation, we were able to show that m vivo, 1 0 0 o / o asialo-
HCG was approximately 50 times less effective than intact HCG in displacing the 
labelled hormone f r o m the ovary, while in vitro the same desialylated preparation was 
at least as effective as intact HCG (f ig. 2 en 3). 
Fig 2. In vivo displacement of l25l-labelled HCG from ovaries of immature female rats by 
graded doses of intact and 100o/o desialylated HCG. 
% Bound ( c p m ) -
6 C o n t r o l s 
5 -
4 -
3 -
2 -
1 -
A A Intact HCG 
• » 1 0 0 % Asialo-HCG 
Ν"· 
0 1 10 100 
( A s i a l o ) - Η C G - m i c r o g r a m s 
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125, Fig. 3. In vitro displacement of l-labelled HCG from ovarian 
homogenates of female pseudo-pregnant rats by graded doses 
of intact and 100ο/ο desialylated HCG. 
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S A M E N V A T T I N G EN CONCLUSIES 
In het eerste artikel van di t proefschrift werd de invloed nagegaan van afsplitsing 
van neurammezuur op de immunologische en biologische activiteit van humaan chorion 
gonadotrofme (HCG). De immunologische activiteit werd radio-immunologisch gemeten, 
de biologische activiteit middels de ascorbmezuur depletie-test (OAAD) en de ventrale 
prostaat test(VPW). Twee gezuiverde HCG preparaten"met een biologische activiteit van 
ongeveer 12000 IE/mg ( O A A D en VPW) en een immunologische activiteit van ongeveer 
5000 IE/mg werden voor deze studies gebruikt. Toenemende percentages neurammezuur 
werden verwijderd door het HCG met stijgende hoeveelheden neuraminidase afkomstig 
van Clostr idium perfrmqens te behandelen. De immunologische activiteit werd door deze 
bewerking met beïnvloed, de biologische activiteit echter wel. 
Verwijdering van 0 to t 2 5 0 / o neurammezuur deed de biologische activiteit met 75 0 / o 
verminderen, zowel m de O A A D als de VPW. Verdere afsplitsing van neurammezuur 
to t 6 2 0 / o deed de biologische activiteit nog sterker verminderen, waarbij echter bleek 
dat de overgebleven activiteit m de VPW aanzienlijk lager was dan m de O A A D . De bio-
logische activiteit nam niet verder af wanneer het percentage afgesplitst neurammezuur 
opgevoerd werd van 6 2 0 / o to t 100 o /o . 
De gevonden verschillen m biologische activiteit gemeten middels de O A A D en de VPW 
na verwijdering van neurammezuur deden vermoeden dat het verlies aan biologische 
activiteit m verband zou kunnen staan met veranderingen m de half-waarde t i jd van HCG 
m plasma. Deze hypothese vormde de basis van de m het tweede artikel beschreven 
onderzoekingen, waarin de invloed werd nagegaan van de mate van afsplitsing van 
neurammezuur op de verdwijnmgssnelheid van HCG uit het plasma. Met behulp van een 
specifieke radio-immunologische bepaling werden de concentraties van immuno-reactief 
HCG m plasma gemeten op verschillende ti jdstippen na intraveneuze injectie van intact 
en met neuraminidase behandeld gezuiverd HCG m schijnzwangere ratten. Verwijdering 
van 0 to t 2 5 0 / o neurammezuur verkortte de half-waarde t i jd met 50 o / o (van 25 naar 
11 minuten). Verdere afsplitsing van neurammezuur to t 6 2 0 / o veroorzaakte een nog 
sterkere verkort ing van de half-waarde t i jd (van 11 minuten to t minder dan 1 minuut ) . 
Vewijdermg van meer dan 6 2 0 / o van het neurammezuur gehalte had geen verdere 
meetbare invloed op de half-waarde t i jd . 
Deze bevindingen leken de hypothese te steunen dat het verlies aan biologische activiteit 
na afsplitsing van neurammezuur, althans voor een deel veroorzaakt werd door de verkor-
t ing van de half-waarde t i jd . 
In het derde art ikel werd het effect bestudeerd van de verwijdering van neurammezuur 
op de biologische activiteit van humaan hypophysair lutemiserend hormoon (HLH) . 
Een gezuiverd H L H preparaat met een neurammezuur gehalte van 2 ,3 0 /o en een biolo-
gische activiteit van 3546 IE/mg (OAAD) en 1910 IE/mg (VPW) werd met neuraminidase 
behandeld waarbij 9 4 0 / o van het neurammezuur werd verwijderd. De biologische acti-
viteit verminderde door deze bewerking aanzienlijk. De overgebleven activiteit bleek 
16,2 0 /o m de O A A D .en 12,5 0 /o m de VPW te z i jn, berekend op de uitgangswaarde. 
De immunologische activiteit vertoonde een significante stijging ten opzichte van de 
oorspronkeli jke waarde (144 0 /o ) . 
Samenvattend werd geconstateerd: 
1. verwijdering van neurammezuur heeft geen invloed op de immunologische activiteit 
van HCG, maar veroorzaakt een significante stijging van de immunologische activiteit 
van L H . 
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2. verwijdering van neuraminezuur leidt zowel tot een vermindering van biologische 
activiteit als tot een verkorting van de half-waarde tijd van HCG. 
3. er bestaat een positieve correlatie tussen de veranderingen die optreden m de biolo-
gische activiteit en de half-waarde tijd van HCG door verwijdering van neuraminezuur. 
Deze bevindingen brachten ons ertoe de volgende hypothese te formuleren: 
Verwijdering van neuraminezuur van HCG, en mogelijk ook van LH, veroorzaakt een 
sneller verdwijnen van deze hormonen uit het plasma waardoor relatief minder hormoon 
de gonade bereikt, met als gevolg een vermindering van de meetbare biologische activiteit. 
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dank je wel, lieve mies 
STELLINGEN 
1 
Het hartloze monster (acardius) ontstaat niet door abnormale circulatieverhoudingen, 
doch is het gevolg van een primair entodermdefect 
O.R. Hommes, Primaire entodermdefecten, 
dissertatie 1957. 
2 
Het verdient aanbeveling om bij vrouwen met een onverklaarde gestoorde obstetrische 
anamnese en een positieve familieanamnese voor diabetes, een behandeling met insuline 
te beproeven, ook al is de glucose tolerantietest normaal. 
S.J.L van der Linden and J.L. Mastboom 
J. Obstet Gynaec. Brit. Cwlth. (in druk) 
3 
De behandeling van anovulatie door middel van wigresectie bij vrouwen met polycystische 
ovaría dient als obsoleet te worden beschouwd. 
4 
De waarde van de hysterosalpingografie bij de diagnostiek van tubaire infert i l i tel i is 
zeer betrekkelijk. 
5 
Om redenen van zowel medische als economische aard dient bij de zorg voor zieken en 
gezonden veel meer aandacht te worden geschonken aan het subsidiariteitsbeginsel. 
6 
De mogelijkheid om op artikelen te promoveren vormt een positieve bijdrage tot een 
betere integratie van wetenschappelijke ambitie m het gezinsleven. 


